A monitored-release study of methrazone in general practice.
Methrazone, a non-steroidal anti-inflammatory drug, was used on a monitored release study in general practice to treat 2,693 patients with rheumatoid or osteoarthritis. In a dose of 200 mg three times daily, it appeared to produce clear benefit in between 50% and 60% of patients. Adverse reactions such as dyspepsia and skin rash led to the drug being withdrawn in 11% of patients. There were three major adverse reactions possibly due to the drug (haematemesis, rectal bleeding and acute purpura), but no cases of severe leucopenia or thrombocytopenia. Methrazone is a useful anti-inflammatory agent. In particular, it is unlikely to cause interactions with other drugs, including cardiac glycosides such as digoxin.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002493:Central Nervous System Diseases / Q000139:chemically induced; D003875:Drug Eruptions / Q000139:chemically induced; D004347:Drug Interactions; D005194:Family Practice; D011298:Feprazone / Q000009:adverse effects / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D010352:Patient Dropouts; D010653:Phenylbutazone / Q000031:analogs & derivatives*
D011298:Feprazone; D010653:Phenylbutazone